 | Up a level |
Moccia, A A; Aeppli, S; Güsewell, S; Bargetzi, M; Caspar, C; Brülisauer, D; Ebnöther, M; Fehr, M; Fischer, N; Ghilardi, G; Krasniqi, F; Lang, N; Mey, U; Mingrone, W; Novak, U; Pfleger, C; Richter, P; Rütti, M; Schmidt, A; Stenner, F; ... (2021). Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. Hematological oncology, 39(2), pp. 196-204. Wiley 10.1002/hon.2830
Bürki, S; Novak, U (2020). Dual Mechanism of Severe Bleeding Diathesis in a Patient with CLL: Acquired Von Willebrand Syndrome and Ibrutinib - Mediated Platelets Dysfunction. Annals of Hematology & Oncology, 7(3) Austin Publishing Group
Reber, R; Chan, WC; Novak, U (2011). Assessing DLBCL subtypes by immunohistochemistry E-Letter in response to Gutierrez-Garcia et al. Blood(117: 4836-43) Washington, D.C.: American Society of Hematology
Novak, U (2010). Molekularbiologie maligner Lymphome für den Nichtspezialisten. Therapeutische Umschau, pp. 501-4. Bern: Huber
Novak, U; Pasqualucci, L; Dalla-Favera, R (2011). Molecular Biology of Lymphomas. In: DeVita, Vincent D.; Lawrence, Theodore S.; Rosenberg, Steven A. (eds.) CANCER: Principles & Practice of Oncology. Lippincott Williams & Wilkins
Novak, U (March 2022). CD19-gerichtete CAR-T-Zell-Therapie in der Schweiz: der klinische Alltag. Leading Opinions. Hämatologie & Onkologie, pp. 18-20. Universimed
